Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push
PositiveFinancial Markets

Bristol Myers Squibb has made a significant move in the biotech sector by acquiring Orbital Therapeutics for $1.5 billion. This acquisition is a strategic step to enhance their cell therapy portfolio, which is crucial for addressing various diseases. It highlights Bristol Myers' commitment to innovation and growth in the field of advanced therapies, potentially leading to groundbreaking treatments for patients.
— Curated by the World Pulse Now AI Editorial System